Clinical Trial Update: High Doses of Candesartan Cilexetil on the Reduction of Proteinuria [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating high doses of candesartan cilexetil for reducing proteinuria has completed; the snippet does not report trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proteinuria

Drugs mentioned

• candesartan cilexetil (candesartan cilexetil)

Snippet

Sponsor: AstraZeneca | Conditions: Proteinuria | Phase 3 | Status: COMPLETED